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Off-pump coronary artery bypass grafting provides
complete revascularization with reduced myocardial injury,
transfusion requirements, and length of stay: A prospective
randomized comparison of two hundred unselected
patients undergoing off-pump versus conventional coronary
artery bypass grafting
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Objective: Retrospective comparisons of selected patients undergoing off-pump
versus conventional on-pump coronary artery bypass grafting have yielded incon-
sistent results and raised concerns about completeness of revascularization in
off-pump coronary artery bypass grafting.
Methods: Two hundred unselected patients referred for elective primary coronary
artery bypass grafting were randomly assigned to undergo off-pump coronary artery
bypass grafting with an Octopus tissue stabilizer (Medtronic, Inc, Minneapolis,
Minn) or conventional coronary artery bypass grafting with cardiopulmonary bypass
by a single surgeon. Revascularization intent determined before random assignment
was compared with the revascularization performed. All management followed
strict, unbiased, criteria-driven protocols. Patients and nonoperative care providers
were blinded to surgical group.
Results: Baseline characteristics were similar. The number of grafts performed per
patient (mean  SD 3.39  1.04 for off-pump coronary artery bypass grafting,
3.40  1.08 for conventional coronary artery bypass grafting) and the index of
completeness of revascularization (number of grafts performed/number of grafts
intended, 1.00 0.18 for off-pump coronary artery bypass grafting, 1.01 0.09 for
conventional coronary artery bypass grafting) were similar. Likewise, the index of
completeness of revascularization was similar between groups for the lateral wall.
Combined hospital and 30-day mortalities and stroke rates were similar. Postoper-
ative myocardial serum enzyme measures were significantly lower after off-pump
coronary artery bypass grafting, suggesting less myocardial injury. Adjusted post-
operative thromboelastogram indices, fibrinogen, international normalized ratio, and
platelet levels all showed significantly less coagulopathy after off-pump coronary
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artery bypass grafting. Patients undergoing off-pump coronary artery bypass graft-
ing received fewer units of blood, were more likely to avoid transfusion altogether,
and had a higher hematocrit at discharge. Cardiopulmonary bypass was an inde-
pendent predictor of transfusion (odds ratio 2.42, P  .0073) by multivariate
analysis. More patients undergoing off-pump coronary artery bypass grafting were
extubated in the operating room and within 4 hours. Postoperative length of stay (in
days) was shorter for off-pump coronary artery bypass grafting (5.1  6.5 for
off-pump coronary artery bypass grafting, 6.1  8.2 for conventional coronary
artery bypass grafting, P .005 by Wilcoxon test). One patient (in the conventional
coronary artery bypass grafting group) required angioplasty for graft closure within
30 days.
Conclusions: When compared with conventional coronary artery bypass grafting
with cardiopulmonary bypass, off-pump coronary artery bypass grafting achieved
similar completeness of revascularization, similar in-hospital and 30-day outcomes,
shorter length of stay, reduced transfusion requirement, and less myocardial injury.
For more than 3 decades, surgical coronaryrevascularization has been accomplished withthe use of cardiopulmonary bypass (CPB) inthe vast majority of cases. However, off-pump coronary artery bypass grafting (OP-CAB) has enjoyed a recent resurgence in in-
terest and popularity, first in South America1,2 and then
worldwide.3,4 This has been fueled by a growing awareness
of the morbidity attributable to CPB and by refinement of
instrumentation to facilitate beating heart surgery.
The diffuse inflammatory response elicited by CPB has
been invoked to explain the small but finite incidence of
serious injury in multiple organ systems, causing numerous
postoperative complications and prolonging hospital length
of stay. CPB, aortic crossclamping, and cardioplegia entail
global myocardial ischemia during the crossclamp interval.
Although effective cardioplegia reduces this risk, myocar-
dial injury may still occur. This is manifested by release of
myocardial enzymes and a small but finite incidence of
Q-wave myocardial infarction. Hemodilution and hemolysis
are direct consequences of CPB and may produce signifi-
cant coagulopathy, necessitating transfusion of blood prod-
ucts.
Although OPCAB now accounts for approximately 18%
of coronary artery bypass grafting (CABG) procedures per-
formed in the United States, as reported by the National
Society of Thoracic Surgeons Adult Cardiac Database Fall
2001 report (data reported through June 2001, http://www.
sts.org), concern has been raised about the difficulty of this
rediscovered operation and the possibility that incomplete
revascularization may compromise patient outcomes.5,6
Those retrospective comparisons favoring OPCAB over
CABG with CPB7 have been appropriately criticized for
bias inherent in patient selection for OPCAB and for “fast-
track” management selectively applied to patients undergo-
ing OPCAB. Thus previous retrospective and nonrandom-
ized comparisons of OPCAB versus CABG with CPB may
have used inadequately matched control groups. Even ret-
rospective studies applying sophisticated statistical analyses
to very large databases8,9 and reporting significant benefits
of OPCAB over CABG with CPB for mortality, stroke, and
many other complications are subject to this criticism.
Moreover, most previous studies have failed to adequately
address legitimate concerns about the completeness of re-
vascularization provided or to document the quality of anas-
tomoses constructed during OPCAB by directly assessing
graft patency. Indeed, all but a very few10 of the dozens of
nonrandomized comparisons published since 1998 reported
statistically fewer grafts performed in the OPCAB group. Of
course, this does not necessarily indicate incomplete revas-
cularization in the OPCAB group, because surgeons during
the “learning curve” may have correctly and consciously
excluded some patients from OPCAB on the basis of cor-
onary anatomy. In particular, multiple grafts to the lateral
wall may be challenging without considerable OPCAB ex-
perience. Nonetheless, this observed difference in number
of grafts between groups does at least indicate an imperfect
composition of the chosen “matched” control groups.
A prospective, randomized study11 among 80 selected
patients heightened concerns about completeness of revas-
cularization in OPCAB when it reported significantly fewer
grafts in the OPCAB group than in the CABG with CPB
group (2.6  0.5 vs 3.1  0.8, P  .04). Two other groups
have published results of randomized comparisons of OP-
CAB versus CABG with CPB with substantial statistical
power. Van Dijk and colleagues12 randomly assigned 281
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selected patients and reported equivalent completeness of
revascularization but only 2.4  1.0 grafts in the OPCAB
group versus 2.6 1.1 grafts in the CABG with CPB group
(P .05). Fewer than 25% of patients enrolled in this study
had three-vessel disease; 78% had normal left ventricular
function. Ascione and associates13 randomly assigned 200
selected patients and performed 2.23  0.83 grafts in the
OPCAB group and 2.31  0.86 grafts in the CABG with
CPB group (difference not statistically significant). None of
these patients required grafting of the distal circumflex
territory, and 80% had left ventricular ejection fractions
greater than 50%. There have been no published reports
comparing OPCAB versus CABG with CPB among ran-
domly assigned patients unselected for coronary anatomy,
ventricular function, or comorbidities.
Methods
Patient Enrollment and Random Assignment
The SMART Study (Surgical Management of Arterial Revascu-
larization Therapies) was designed to rigorously compare com-
pleteness of revascularization, clinical outcomes, and resource use
in unselected patients referred for elective, primary CABG ran-
domly assigned to undergo OPCAB with an Octopus tissue stabi-
lizer (Medtronic, Inc, Minneapolis, Minn) or CABG with CPB. In
an effort to minimize variability, all procedures were performed by
a single experienced surgeon (JDP), and all patient management
was conducted by a single team according to strict, unbiased,
blinded, criteria-driven protocols. A sincere effort was made to
enroll patients representative of the general patient population
referred for CABG in the United States in the years 2000 and 2001.
Thus patients were not excluded on the basis of any preoperative
comorbidity or any pattern of coronary artery disease. Only pa-
tients in cardiogenic shock and those requiring preoperative intra-
aortic balloon pump counterpulsation were excluded from the
study for cardiac reasons. Patients who had chronic renal insuffi-
ciency with a creatinine level greater than 2.5 mg/dL were eligible
for enrollment in the study but were exempt from having postop-
erative cardiac angiography performed. Patients who were hemo-
dialysis dependent, however, were eligible for enrollment and
were asked to participate in postoperative angiography. An attempt
was made to randomly assign 1 patient each operative day. Each
patient referred was screened and asked to volunteer. This process
continued each day until 1 patient had agreed to participate in the
study for the next operative day. This was done to facilitate
accurate and complete data acquisition in the light of manpower
limitations. Thus the 200 randomly assigned patients were not in
fact consecutive referrals to this surgeon. After approval by the
institutional review board of Emory University, Atlanta, Ga, the
first patient was enrolled on March 20, 2000. The 200th patient
completed enrollment on August 10, 2001. During this 17-month
period, the operating surgeon performed primary, elective, isolated
CABG for a total of 465 patients. Although 64% of all eligible
patients were screened and either enrolled or refused participation,
the other 36% of the population were not approached for various
logistic reasons, such as a previous patient having already con-
sented to participate the next day, unavailability of clinical re-
search staff, weekend procedures, or surgical scheduling. Thus
43% of the total eligible patients during this period were enrolled
in the SMART Study. Three patients were found to require mitral
valve repair or replacement after random assignment and were
subsequently excluded from the study. One patient withdrew from
the study immediately after surgery. His preoperative and acute
hospital data were included in the analysis, but no long-term data
were collected.
Patients were randomly assigned by means of a computer-
generated random number table. This was done for each patient
after the operating surgeon had documented the intended revascu-
larization to be performed, which was based on review of the
preoperative coronary arteriogram. Random assignment was strat-
ified by sex and diabetic status to insure roughly equal numbers of
patients within strata defined by these prognostically relevant
characteristics. Random assignment was carried out separately
within each stratum with randomly permuted blocks of size 4 and
6 to preserve approximate balance and prevent correct prediction
of the next assignment by the clinical recruiting staff.
Crossing Over Between Groups and Blinding to
Group Assignment
Patients were allowed to cross over between groups whenever the
treating surgeon considered that this would be unequivocally in the
patient’s best interest. All patients, their families, referring cardi-
ologists, and nonoperative care providers were blinded as to group
assignment. This blinding will be maintained through the 1-year
follow-up period.
Patient Management Protocols
Patients participating in the SMART Study were identified simply
as “SMART Study patients,” and their care was managed accord-
ing to strict, unbiased, criteria-driven, printed protocols. There
protocols were developed specifically to standardize management
of study patients and were applied identically to both groups.
Protocols controlled preoperative care, anesthesia and analgesia
(before, during, and after the operation), extubation, intensive care
unit management and transfer, ambulation, diet, medications,
transfusion, all laboratory and radiologic examinations, and dis-
charge planning. Each of these protocols was translated to patient
order forms and placed on the chart of each patient enrolled. Thus,
for instance, each study patient received identical anesthetic pre-
medication and identical anesthesia in the operating room. A
separate, defined protocol determined whether an individual pa-
tient was extubated in the operating room or in the intensive care
unit. Each patient was required to meet specific criteria to be
extubated, and each patient was extubated as soon as these criteria
were met. Thus the opportunity for biased or selective “fast-
tracking” of patients undergoing OPCAB was minimized or elim-
inated.
Data Acquisition and Management
Preoperative data acquisition included a complete assessment of
patient demographics, preoperative risk factors, and preoperative
medications. Preoperative neurologic and quality of life assess-
ments included administration of the National Institutes of Health
Stroke Scale by a trained physician assistant and the Euroquol and
SF-36 self-reporting questionnaires. Table 1 reports the timing of
various investigations.
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All data were gathered prospectively and recorded by one of
two clinical research nurse coordinators assigned to the manage-
ment of the study. Case report forms (CRFs) were designed and
developed with a Teleform software package (TELEform Elite;
Cardiff Software Ltd, Vista, Calif). Completed CRFs were logged
on to the “CRF log form” and copied and transported to Emory
Center for Outcomes Research (ECOR), where each CRF was
again logged into the ECOR system by an assigned project data
manager. The Teleform CRF was then electronically scanned and
imported into a predesigned ACCESS relational database (Mi-
crosoft, Redmond, Wash). Data integrity and completeness were
monitored and maintained through manual and electronic mecha-
nisms. Copies of each CRF were stored within a locked and
monitored office environment. All study data were therefore de-
posited and managed in an independent data warehouse, maintain-
ing an arm’s-length distance between the clinical team and the data
repository. Serial 12-lead electrocardiograms (ECGs) were evalu-
ated and scored for perioperative myocardial infarction according
to the Minnesota Code at an external ECG core laboratory (St
Louis University Core ECG Lab, St Louis, Mo). These data were
independently delivered to ECOR. All data analysis, data interpre-
tation, and manuscript review were performed under the direction
of a doctoral-level biostatistician at ECOR. The sponsors of this
trial played no role in study design; in the collection, analysis, and
interpretation of data; or in the writing of this report.
Power Calculations and Statistical Analysis
The sample size was chosen for the ability to detect a difference of
5% between treatment groups in the primary end point, graft
patency. Assuming a conservative estimate of an average of 3
grafts performed per patient, and making the further assumption
that patency outcomes of grafts within a patient are independent,
100 patients in each treatment arm would yield 78% power to
detect a difference in patency rate of 5%, assuming a type 1 error
rate of .05. Eighty percent power would be achieved with an
average of 3.08 grafts per patient. Although an overall higher
number of grafts per patient was anticipated, the nonindependence
of patency outcomes within patients, which are taken into account
in the analysis, would effectively lower the power to a small
extent. Overall, 100 patients in each treatment group should con-
servatively yield 80% power to detect the 5% difference in patency
rates that is considered clinically important.
The index of completeness of revascularization (ICOR, number
of grafts performed/number of grafts intended) was compared
between treatment arms with the Wilcoxon rank sum test. Dichot-
omous morbidity and mortality outcomes were analyzed with the
Fisher exact test. All data analysis was according to intent to treat.
All 4 patients who crossed over between groups were also ana-
lyzed according to intent to treat. Analysis of covariance was used
to compare postoperative laboratory values between treatment
groups after adjustment for preoperative levels. Discrete data are
presented as percentages; continuous data are presented as mean
SD.
Follow-up
All 192 eligible patients completed personal or telephone inter-
views approximately 30 days after surgery. These interviews as-
sessed adverse events, complications, readmissions, and reinter-
ventions.
Surgical Technique
General. Surgical access to the heart was through a
standard median sternotomy in all cases. All incisions and
closure techniques were the same for both groups, limiting
variability and maintaining blinding of group assignment
for patients, families, and referring cardiologists. A cell
saver reservoir (COBE Cardiovascular, Inc, Arvada, Colo)
was set up for all patients in both groups. Blood was spun
down and returned to all patients when the quantity was
sufficient. All patients had epiaortic ultrasonography per-
formed immediately after pericardiotomy. Patients discov-
ered to have a heavily calcified or severely atheromatous
ascending aorta (grade 3) that precluded safe cannulation
or crossclamping were treated with an aortic “no-touch”
technique. This required that such patients randomly as-
signed to OPCAB had internal thoracic arteries used for sole
















Coronary angiography X X X
Complete history and physical examination X
Physical assessment X X X
Angina assessment X X
Medication history X X X
ECG X X X
National Institutes of Health Stroke Scale X X X
SF-36 and Euroqol X X X X
Laboratory tests X X X X X X
Diffusion-weighted magnetic resonance imaging X
Transesophageal echocardiogram X
Chest radiograph X X X X X
Pulmonary function test X X
Resource use X X X X X
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coronary inflow and those randomly assigned to CABG
with CPB were converted to the OPCAB group. Patients
randomly assigned to the off-pump technique for whom
complete revascularization was not technically feasible
without the use of CPB were allowed to cross over to the
on-pump group. Thus enrollment in this study did not com-
promise the standard of care provided to any patient. Fine
monofilament suture (8-0 Surgipro; United States Surgical
Corporation, Norwalk, Conn) was used for all distal anas-
tomoses, with the exception of heavily calcified, large-
caliber coronaries that could not be penetrated with an 8-0
needle. A humidified carbon dioxide blower (Medtronic
DLP, Minneapolis, Minn) was used to disperse blood from
the anastomotic site during construction of distal anastomo-
ses in both groups. Proximal anastomoses were performed
with 5-0 or 6-0 Surgipro suture for venous anastomoses and
6-0 or 7-0 Surgipro suture for arterial anastomoses to the
aorta.
OPCAB technique. OPCAB was performed with the
Medtronic Octopus II (March 2000-May 2000) and Octopus
III (May 2000-August 2001) stabilizing devices for coro-
nary stabilization and deep pericardial traction sutures for
cardiac displacement and presentation. This was accom-
plished according to techniques previously described else-
where, with great care taken to maintain hemodynamic
stability (mean arterial blood pressures 65 mm Hg)
throughout the operation.14 Perfusion-assisted direct coro-
nary artery bypass with the Quest Medical myocardial pro-
tection system (Quest Medical, Dallas, Tex) was used at the
discretion of the surgeon in 1 patient in the OPCAB group
with critical left main coronary artery stenosis and pro-
foundly depressed left ventricular ejection fraction.15
CABG with CPB technique. Conventional CABG with
CPB was accomplished with every effort made to minimize
the impact of CPB. Patients without diabetes received 250
mg methylprednisolone sodium succinate (Solu-Medrol) in-
travenously before induction of anesthesia in the CABG
with CPB group only. Cannulation and single aortic clamp-
ing were guided by the results of individual epiaortic ultra-
sonographic scanning of the ascending aorta. The SARNS
“soft-flow” aortic cannula, a two-stage venous cannula, and
retrograde blood cardioplegia catheter were used for all
patients in the CABG with CPB group (3M Health Care,
Ann Arbor, Mich). A phrenic nerve pad was used to ther-
mally insulate the heart and to protect the phrenic nerve.
The patients were routinely cooled to 34°C for operations
when 3 or fewer grafts were anticipated. When 4 or more
grafts were anticipated, the patient was cooled to 32°C. The
COBE disposable arterial-venous circuit was used with a
40-m arterial line filter and 0.5-inch thick-walled pump
head boot. The COBE CML Duo oxygenator and the COBE
heart-lung machine were used. Hemoconcentration was
used for patients in congestive heart failure or renal failure
and for those whose venous reservoir accumulated more
than 2 L of volume. The Quest Medical Myocardial Protec-
tion System was used to deliver cold (5°C-8°C), intermit-
tent, high-potassium antegrade and retrograde 4:1 blood
cardioplegia in all on-pump cases.
Results
Three patients were found by intraoperative transesophageal
echocardiography to require mitral valve repair or replace-
ment after random assignment and were subsequently ex-
cluded from the study. Thus data analysis was based on 98
patients in the OPCAB group and 99 patients in the CPB
group. Baseline characteristics were similar between the
groups (Table 2). Three patients randomly assigned to con-
ventional CABG with CPB in whom epiaortic ultrasonog-
raphy demonstrated heavy calcification or severe athero-
sclerosis of the ascending aorta were crossed over to the
OPCAB limb and treated with an aortic “no-touch” tech-
nique with internal thoracic artery conduits for coronary
inflow. Conversely, 1 patient randomly assigned to the
OPCAB group had a tear occur in the right ventricle during
left internal thoracic artery anastomosis to a deep intramyo-
cardial left anterior descending coronary artery, and the
procedure was intraoperatively converted to CPB at the
surgeon’s discretion.
Table 3 reveals that complications either in hospital or
within 30 days of the operation were similar between
groups. There were 3 deaths either in the hospital or within
30 days of surgery in the OPCAB group and 2 deaths in the
CABG with CPB group. All 3 patients in the OPCAB group
who died were extubated on the day of surgery, had cardiac
catheterization on postoperative day 1 demonstrating that all
grafts were patent, and variously died later of fulminant
pseudomembranous colitis on postoperative day 32, hepa-
rin-induced thrombocytopenia on postoperative day 44, and
a primary arrhythmia on postoperative day 3. The patient
with the primary arrhythmia also underwent autopsy, which
demonstrated that all grafts were still patent. Neither of the
2 patients in the CABG with CPB group who died recovered
from surgery to undergo postoperative catheterization. One
died on postoperative day 7 of a massive perioperative
cerebral infarction, whereas the other required reexploration
for bleeding and later acquired adult respiratory distress
syndrome and multisystem organ failure, dying on postop-
erative day 18. Neither had an autopsy performed. One
patient in the OPCAB group and 2 patients in the CABG
with CPB group had perioperative strokes. All perioperative
strokes were confirmed by computed tomographic scanning
and by a neurologist’s examination. There was no signifi-
cant difference in the incidence of postoperative atrial fi-
brillation between groups (n  16/98 for OPCAB vs n 
22/99 for CABG with CPB, P  .367).
The number of grafts performed per patient (3.39 1.04
for OPCAB vs 3.40  1.08 for CABG with CPB) and the
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ICOR (1.00  0.18 for OPCAB vs 1.01  0.09 for CABG
with CPB) were similar between groups. Likewise, ICOR
was similar between groups for the lateral wall (1.00 0.18
for OPCAB vs 1.01  0.09 for CABG with CPB). Thus in
this study of 197 randomly assigned patients unselected for
coronary anatomy, completeness of revascularization (as
assessed by ICOR) was statistically similar between the
OPCAB and CABG with CPB groups (Table 4). Moreover,
arterial conduits constituted a similar proportion of grafts in
both groups (41.3% for OPCAB vs 40.8% for CABG with
CPB, difference not statistically significant). Complete graft
patency data will be presented after completion of serial
cardiac catheterizations at 1-year follow-up.
Serum albumin was higher in the OPCAB group (2.46
0.49 g/dL vs 2.16  0.46 g/dL, P  .001) in the early (2
hours) postoperative period, suggesting less hemodilution in
the OPCAB group. Postoperative thromboelastogram indi-
ces determined without heparinase were equivalent; indices
measured with heparinase were significantly higher in the
OPCAB group, indicating less residual coagulopathy after
heparin neutralization. After adjustment for baseline values,
postoperative thromboelastogram indices, fibrinogen levels,
TABLE 2. Patient characteristics
Variables OPCAB (n  98)
CABG with CPB
(n  99) P value
Age (y, mean  SD) 62.2 11.1 62.5 9.45 .973
Gender (No. female) 22 (22%) 23 (23%) .999
BMI (kg/m2, mean  SD) 29.4 6 28.1 4.5 .104
Baseline EF .696
55% 46 (52%) 47 (52%) —
45%-54% 19 (22%) 20 (22%) —
35%-44% 14 (16%) 11 (12%) —
25%-34% 5 (6%) 7 (5%) —
25% 4 (5%) 6 (7%) —
Previous MI 34 (35%) 31 (31%) .649
0-7 d 13 (14%) 9 (9%) —
7 d 1 (1%) 2 (2%) —
21 d 12 (13%) 15 (15%) —
Previous CVA 1 (1%) 9 (9%) .018
Previous TIA 3 (3%) 1 (1%) .621
COPD 10 (10%) 8 (8%) .630
Current smoker 27 (28%) 31 (31%) .640
Diabetes 32 (33%) 33 (30%) .999
Insulin 9 (29%) 10 (13%) .999
Oral agent 22 (12%) 24 (30%) .863
Hypertension 64 (65%) 61 (62%) .650
Previous angioplasty 23 (23%) 15 (15%) .206
Prior stent 9 (9%) 6 (6%) .430
Hypercholesterolemia 48 (49%) 47 (48%) .999
Previous peripheral
vascular surgery
13 (14%) 10 (11%) .657
Renal failure 4 (4%) 2 (2%) .682
Dialysis dependence 1 (1%) 1 (1%) .999
NYHA functional class III
or IV
2 (2%) 1 (1%) .620
CCS class III or IV 24 (25%) 12 (12%) .027
Preoperative
medications
Aspirin 53 (54%) 57 (58%) .668
ACE inhibitors 41 (42%) 37 (37%) .562
-Blocker 41 (42%) 48 (48%) .391
Calcium-channel
blocker
24 (24%) 22 (22%) .739
Diuretic 16 (16%) 11 (11%) .308
Statin 40 (41%) 33 (33%) .304
All data are numbers of patients (with percentages) unless otherwise
stated. BMI, Body mass index; EF, ejection fraction; MI, myocardial infarc-
tion; CVA, cerebrovascular accident; TIA, transient ischemic attack; COPD,
chronic obstructive pulmonary disease; NYHA, New York Heart Associa-
tion; CCS, Canadian Cardiovascular Society; ACE, angiotensin-converting
enzyme.







P valueNo. % No. %
Operative mortality 1 1 2 2 .999
In operating room 0 0 0 0
In hospital 30 d 1 1 2 2 .999
In hospital 30 d 2 2 0 0 .246
Out of hospital 30 d 0 0 0 0
Cardiac
Reoperation for bleeding 1 1 2 2 .999
Reoperation for graft occlusion 0 0 0 0 .999
Angioplasty 0 0 1 1
Stent 0 1 1 .999
Myocardial infarction, new Q
wave
1 1 2 2 .999
Angina 0 1 1 .999
Arrhythmia, atrial fibrillation 16 16 22 22 .367
Arrhythmia, ventricular 1 1 2 2 .999
Arrhythmia, permanent
pacemaker
0 0 0 0
Neurologic
Permanent stroke 1 1 2 2 .999
Transient ischemic attack 1 1 0 0 .497
Renal
New failure* 1 1 2 2 .999
New dialysis 2 2 0 0 .246
Pulmonary
Pleural effusion, thoracocentesis 9 9 17 17 .096
Infection†
Deep sternal 2 2 1 1 .621
Superficial sternal 4 4 7 7 .537
Conduit harvest site 9 9 10 10 .999
Other
Gastrointestinal 3 3 2 2 .682
bleeding
*New renal failure was considered in the presence of creatinine greater
than 2.0 mg/dL or 50% increase in creatinine with respect to baseline.
†Deep sternal infection required major surgical de´bridement or muscle flap
closure and antibiotic treatment; superficial sternal infection required
antibiotics with or without minor irrigation and de´bridement only; conduit
harvest site infection required antibiotics with or without irrigation and
de´bridement only.
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international normalized ratios, and platelet levels all
showed significantly less coagulopathy after OPCAB. In-
terestingly, cumulative chest tube output did not differ sig-
nificantly between the groups at 4, 8, or 12 hours, although
there was a trend toward more frequent thoracocentesis in
the CABG with CPB group (n 17/99) than in the OPCAB
group (n  9/98, P  .096). Patients in the OPCAB group
received fewer units of blood, were more likely to avoid
transfusion altogether, and had higher hematocrit at dis-
charge (differences between groups were determined after
adjustment for baseline levels by analysis of covariance;
Table 5). This difference in transfusion requirement was
most pronounced on the day of surgery. CPB was an inde-
pendent predictor of transfusion (odds ratio 2.42, P 
.0073) according to multivariate analysis. Incidences of
reoperation for bleeding were similar (n  2/99 for CABG
with CPB vs n  1/98 for OPCAB).
Mean serum levels of creatine kinase MB and troponin I
were significantly lower in the OPCAB group at 8, 16, 24,
and 48 hours after the operation, suggesting less myocardial
injury (Figure 1). Only 1 patient in the OPCAB group and
2 in the CABG with CPB group had new Q waves by
Minnesota Code criteria, as determined at an independent,
external core laboratory (Table 6). No patient in either
group had both new Q waves and myocardial enzyme
release in excess of 5 times the upper limit of normal. Five
patients in the CABG with CPB group had new right bundle
branch block on postoperative ECG, as opposed to none in
the OPCAB group, a difference that approached statistical
significance. There were no other significant differences in
serial ECGs between the groups.
More patients in the OPCAB group met extubation cri-
teria in the operating room (n  45/98 for OPCAB vs n 
32/99 for CABG with CPB, P  .057) and within 4 hours
after the operation (n  73/95 for OPCAB vs n  50/95
CABG with CPB, P  .001). All patients in the OPCAB
group were extubated within 24 hours after the operation,
whereas 5 patients in the CABG with CPB group did not
meet extubation criteria until more than 24 hours after the
operation (P  .059). Two patients in each group were
reintubated for cardiopulmonary indications during the ini-
tial hospitalization. With all patient management governed
by uniform, unbiased protocols, postoperative length of stay
was significantly shorter after OPCAB (5.1 6.5 days) than
after CABG with CPB (6.1  8.2 days, P  .005 by
Wilcoxon test). Interestingly, most of this difference was in
length of stay after transfer from the intensive care unit
(Table 7). Importantly, only 1 patient in each group required
discharge to a short-term rehabilitation facility; all others
were discharged to home.
Thirty-day Follow-up
Despite earlier discharge from hospital, patients in the OP-
CAB group were no more likely to be readmitted than were
those in the CABG with CPB group. Five patients in the
OPCAB group and 6 patients in the CABG with CPB group
were readmitted to any hospital for any reason within 30
days after the operation. The causes of readmission are
listed in Table 8. One patient in the CABG with CPB group
had early graft failure, recurrent angina, and a myocardial
infarction with ventricular fibrillation that necessitated
emergency angioplasty and stent placement within 30 days
after the operation. No other patient in either group had
recurrent angina. None underwent repeated surgical revas-
cularization.
Discussion
Previous nonrandomized comparisons of OPCAB and
CABG with CPB applying sophisticated statistical methods
to large databases8,9 have reported significant reductions in
risk-adjusted mortality, stroke, acute renal failure, pro-
longed ventilator dependence, reexploration for bleeding,
and other complications with OPCAB. However, legitimate
criticism of these conclusions has centered on the nonran-
domized nature of the studies and the inherent bias of
patient selection for OPCAB. Although statistical methods
of risk adjustment and modeling have been applied in ear-
nest, they are imperfect techniques. It is important to note
that in Cleveland and coworkers’ rigorous analysis of the
Society of Thoracic Surgeons database,8 the CABG with
CPB group had greater proportions of patients with three-
vessel disease and of urgent and emergency cases than did
the OPCAB group, illustrating the role of patient selection
in determining the composition of these groups.
Randomized comparisons of OPCAB and CABG with
CPB are therefore necessary to obviate these concerns.
However, even the larger randomized studies to date,12,17
including this report, have limited statistical power to detect
TABLE 4. Completeness of revascularization
Variable OPCAB (n  98) CABG with CPB (n  99) P value
Grafts per patient 3.39 1.04 3.40 1.08 .829*
ICOR 1.01 0.18 1.00 0.09 .219*
ICOR lateral wall 0.97 0.23 0.98 0.10 .857*
Arterial grafts (%) 41.3% 40.8% .937
*By Wilcoxon test.
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differences between groups in end points that occur infre-
quently. No difference was found in mortality, stroke, peri-
operative myocardial infarction, or acute renal failure in
either this study or previous randomized studies.
This study was designed to evaluate the crucial end
points of completeness of revascularization and graft pa-
tency. Although 1-year graft patency data will not be avail-
able until after August 2002, results presented here demon-
strate comparable completeness of revascularization in the
two treatment groups, despite the fact that there was no
exclusion of patients from this study on the basis of coro-
nary anatomy, left ventricular function, or other comorbidi-
ties. All patients referred for elective, primary, isolated
CABG were considered eligible. The documentation of the
intended revascularization before random assignment of
patients minimized bias in the evaluation of completeness of
revascularization performed. Although many authors have
reported difficulty grafting the lateral wall of the left ven-
tricle without CPB in their early experience,12,16 this study
was undertaken after the operating surgeon had accumu-
lated a personal experience in excess of 350 OPCAB cases.
Thus the achievement of complete revascularization of the
lateral wall in unselected patients by an experienced OP-
CAB surgeon has been demonstrated. Although it would be
inappropriate to generalize these results to surgeons early in
their experience with OPCAB, it is reasonable to believe
Figure 1. Serial postoperative measures of myocardial enzyme release were significantly lower in OPCAB (dark
bars), than in CABG with CPB (light bars), suggesting less myocardial injury. A, Creatine kinase MB; B, troponin
I.
TABLE 5. Coagulopathy and transfusion
Variable OPCAB CABG with CPB P value
Thromboelastogram index
Chest closed, without heparinase 0.34 8.82 (n 87) 0.29 2.63 (n 76) .850
Chest closed, with heparinase 3.01 1.81 (n 83) 0.62 3.5 (n 75) .001*
International normalized ratio, early postoperative 1.23 0.18 (n 97) 1.35 0.19 (n 99) .001*
Fibrinogen (mg/dL), early postoperative 410.5 110.9 (n 89) 331.8 87.35 (n 98) .001*
Platelets (103 cells/L), early, postoperative 194.2 57.3 (n 94) 136.7 42.5 (n 99) .001*
Hematocrit (%)
Postoperative d 3 29.3 4.16 (n 88) 28.2 3.23 (n 98) .05*
Discharge 30.6 3.74 (n 98) 29.5 3.30 (n 99) .05*
Cumulative packed red blood cells (U/pt), surgery to
postoperative d 3
0.40 0.77 (n 98) 0.61 1.79 (n 99) .013
Patients receiving any packed red blood cells (No.),
surgery to postoperative d 3
25 (26%) 44 (44%) .007
*Differences between groups after adjustment for baseline level (analysis of covariance).
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that similarly complete revascularization would be achieved
by other surgeons who have developed extensive experience
with OPCAB techniques. Thus broad application of OP-
CAB techniques to patients with multivessel disease need
not lead to incomplete revascularization, with its docu-
mented negative consequences.17
Previous publications have documented the strong asso-
ciation between serum evidence of myocardial necrosis and
future adverse cardiac events in patients undergoing percu-
taneous interventions18 and CABG with CPB.19 Although it
is possible that some of the myocardial enzyme release in
the CPB group was caused by cannulation of the right
atrium, it is likely that the large majority derived from
ventricular myocardium. Thus the finding that serum levels
of myocardial enzymes were lower in the OPCAB group
than in the CABG with CPB group at all time points
measured is of particular interest. This result is consistent
with those of previous randomized12,20 and nonrandom-
ized21 comparisons. Planned longitudinal follow-up of these
two randomized groups of patients will allow documenta-
tion of longer-term outcomes correlated with perioperative
elevation in serum levels of myocardial enzymes.
Among the various reported benefits of OPCAB relative
to CABG with CPB, reduction in transfusion requirement
has been remarkably consistent across multiple stud-
ies.7,12,22 This study found that multiple indices of coagu-
lopathy were significantly less deranged in OPCAB than in
CABG with CPB and that patients undergoing OPCAB
received fewer units of blood, were more likely to avoid
transfusion altogether, and had a higher hematocrit at the
time of hospital discharge. Interestingly, cumulative chest
tube output was not significantly different between groups
during the first 12 hours, despite the demonstrated differ-
ence in coagulopathy and the fact that most of the difference
in transfusion requirement was seen during the day of
surgery. Thus it seems likely that the cardiopulmonary
circuit itself either consumes or damages red blood cells to
some degree, causing removal of these cells by the reticu-
loendothelial system in the first hours after surgery. A cell
saver device was used in every case, to equalize efforts
between groups to preserve red cell mass.
As economic considerations influence medical decision
making to an increasing degree worldwide, the lengths of
stay associated with alternative methods of surgical coro-
nary revascularization are increasingly relevant. Consistent
with previous randomized comparisons of selected pa-
tients,12,17 this study of unselected patients with multivessel














block (pulse rate 120
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(n  99) P value
Length of stay
Surgery to discharge (d,
mean  SD)
5.1 6.5 6.1 8.1 .005
Intensive care unit (d,
mean  SD)
23.9 14.5 26.8 24.9 .820
Readmitted to intensive
care unit (No.)




45 (46%) 32 (32%) .057
Extubated 4 h (No.) 73 (77%) 50 (53%) .001
Extubated 24 h (No.) 0 (0%) 5 (5%) .059
Reintubated during
hospitalization (No.)
2 (2%) 2 (2%) .999
Skin to skin time (h, mean
 SD)
3.40 0.97 3.41 0.81 .626
Operating room time (h,
mean/SD)
4.77 0.98 4.69 0.85 .407








No. % No. %
Atrial fibrillation 0 0 3 3
Ventricular fibrillation 0 0 1 1
Stent placement 0 0 1 1
Angina 0 0 1 1
Atypical chest pain 1 1 0 0
Gastrointestinal bleeding 0 0 1 1
Pleural effusions, thoracocentesis 1 1 0 0
Subcutaneous emphysema 1 1 0 0
Thrombectomy, catheter extremity 0 0 1 1
Deep sternal wound infection 0 0 1 1
Superficial sternal infection 0 0 1 1
Harvest site infection 2 2 0 0
All differences not significant.
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disease demonstrated that OPCAB shortened postoperative
length of stay by 1 full day. With all other outcome mea-
sures either equivalent or superior for the OPCAB group,
the decrease in length of stay may prove to be an important
influence on third-party payers and institutional administra-
tors.
Conclusion
Relative to CABG with CPB in this prospective, random-
ized study of 200 unselected patients undergoing elective
primary CABG, OPCAB achieved comparable complete-
ness of revascularization and similar in-hospital and 30-day
outcomes, shorter length of stay, reduced coagulopathy and
transfusion requirement, and less myocardial injury.
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Discussion
Dr Bruce W. Lytle (Cleveland, Ohio). First, I think that this is
a pretty good study. These types of studies where you randomly
assign a surgical procedure are not easy to do, and although it
would always be nice to have more patients, it is difficult to get
even 200 patients into a protocol like this. The random assignment
was not consecutive, but in reading the randomization protocol it
certainly seems reasonable. Although I do not completely under-
stand all the statistics that were used to do it, that is just because
I do not understand those kind of statistics. It seems to me that this
is a fair random sample. Second, the differences in outcomes were
Surgery for Acquired Cardiovascular Disease Puskas et al
806 The Journal of Thoracic and Cardiovascular Surgery ● April 2003
A
CD
very small. A lot of the difficulties in interpreting data concerning
on-pump and off-pump surgery, even with nonrandom studies, has
been that early outcomes do not appear to be much different.
My first question is, are the differences that you noted in
enzyme elevation clinically important? It seems to me that those
differences, although statistically significant, are not vast. Do you
plan to establish the importance of those differences with long-
term follow-up?
My second question is, when you talk about arterial grafts,
there are a lot of different kinds of arterial grafts. My sense is that
this is sort of a left internal thoracic artery to anterior descending
and then radial to something else kind of study, which is a standard
technique but not the same as complex internal thoracic artery
grafting. Is that the case?
My third and final question is, you used the perfusion-assisted
direct coronary artery bypass (PADCAB) type strategy, which I
know that you have advocated in other work, for only 1 patient in
this group to keep things standard, and with the good results of
your standard off-pump technique, do you think that the other
strategy is no longer necessary? What are your feelings about that?
Dr Puskas. Thank you, Dr Lytle. We have all benefited from
your leadership in the field of CABG and your careful examination
of outcomes. Your first question was in regard to the difference in
enzyme release and whether that is a clinically important differ-
ence. The Q-wave infarct rate was not statistically different be-
tween groups. The enzyme release clearly was statistically differ-
ent between groups. It may be that the prolonged length of stay, 1
more day, in that group had something to do with enzyme release
or myocardial injury, or it may be that we need longer longitudinal
follow-up of these groups to discover adverse cardiac events that
may occur later. Certainly in the immediate in-hospital period, the
difference in enzyme release was not correlated with dramatically
different cardiac outcomes; the infarct rate was not significantly
different, and the time spent in the intensive care unit was not
significantly different. The difference in length of stay was after
intensive care unit transfer for the most part. So we do intend to
follow up these patients through time. We will be doing annual
follow-ups for the foreseeable future and trying to correlate ad-
verse cardiac events with preoperative and postoperative events
and markers from the hospital stay.
Your second question related to arterial grafting. You are
correct in assuming that with 41% of all grafts being arterial
conduits, the left internal thoracic artery was essentially a uniform
graft for all patients. Left radial artery grafting was also very
common. We did, however, have several bilateral thoracic arteries,
both in situ or as composite grafts, and in several cases composite
grafts were taken off the internal thoracic pedicles and anasto-
mosed to the lateral wall in either a surgical Y or sequential
fashion to avoid manipulation of the ascending aorta. So there
were a handful, or a couple of handfuls, of what you might
consider complex arterial grafts with composite right off left
internal thoracic artery anastomoses to multiple lateral wall ves-
sels. As you know, that is not often an absolute necessity, and our
standard grafting procedure was left internal thoracic artery to the
left anterior descending coronary artery, left radial artery to the
biggest lateral wall graft and veins to the right side.
Your third question related to PADCAB and our use of it. We
did use the PADCAB for 1 procedure in the OPCAB group, a
complex five-vessel CABG on a morbidly obese man with a
profoundly depressed left ventricular ejection fraction and preop-
erative myocardial infarction. We considered the PADCAB to be
helpful in keeping that man in stable condition during the opera-
tion. I think that it is also helpful during one’s learning curve and
for treating similar patients after one’s learning curve. I think it
does play a role. But this study was not directed to studying the
benefit of PADCAB, so we tried to limit its application in this
study to avoid confounding influences.
Dr Lawrence I. Bonchek (Lancaster, Pa). Completion of such
a randomized study is a considerable achievement, and I congrat-
ulate Puskas and coworkers. It is interesting that another random-
ized study by Jansen and coworkers from The Netherlands, re-
cently published in Circulation, found that the only major benefits
of OPCAB were less release of cardiac enzymes and shorter length
of stay. Neither that study nor this revealed differences where we
would have hoped to see them, in the incidences of neurologic
deficits, atrial fibrillation, and renal or pulmonary complications.
First, can you discuss the significance of the difference in
enzyme release? Because in your study OPCAB was done with
clamping of single arteries and thus only brief regional ischemia,
whereas CABG with CPB was done with prolonged global isch-
emia and cardioplegic cell membrane paralysis, the difference in
enzyme release is understandable. Of course, CABG with CPB can
also be done with single-vessel occlusion without cardioplegia, as
is done by our group and many others, which might well eliminate
any difference in enzyme release between the two techniques,
except for the unavoidable release related to cannulation of the
right atrium in on-pump cases. I therefore suspect that the differ-
ences in enzyme release are unimportant.
Second, it is important to note that these excellent results were
achieved by an exceptional surgeon. This does not reassure me that
OPCAB is for everyone. In fact, in large groups that do a lot of
OPCAB procedures, most of the cases are done by a few surgeons.
Would you also comment on that observation?
And finally, because you were kind enough to discuss this
protocol with me before you began the study, I know that one of
your objectives was to use blinding as much as possible; however,
you did not discuss that in your presentation. Certainly if the
caregivers who made the decision for hospital discharge were not
blinded, that is a highly subjective decision.
Dr Puskas. Indeed, Larry and I did have several conversations
about the proposed strategy for designing this study about 4 years
ago, and he raises some of the same concerns today. Actually, I did
mention in my earlier presentation that all management was ac-
cording to written, unbiased, criteria-driven protocols and that all
the nonoperative care providers, patients, their families, and refer-
ring cardiologists, as well as the nursing staff, were blinded to
group assignment. The patients were identified only as study
patients, and whether the procedure was OPCAB or CABG with
CPB was not revealed unless it was essential for appropriate
clinical management.
Your first question, Dr Bonchek, related to Jansen and col-
leagues’ report from Utrecht of a randomized study where they
selected patients not requiring lateral wall grafts and also noted a
decrease in creatine kinase MB release and a shorter length of stay.
That study enrolled, I believe, 281 patients; ours enrolled 200. As
you well know, with the statistical power of those numbers, it is
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unlikely and indeed unexpected that we would be able to demon-
strate statistically significant changes in outcomes that occur in-
frequently. Specifically, mortality, stroke, and similar infrequent
events are not going to be demonstrated to be different until we
have a multicenter, prospective, randomized trial enrolling at least
1000 patients. Our best evidence that OPCAB does reduce those
events comes from Cleveland and others, who have carefully
analyzed the Society of Thoracic Surgeons database of many tens
of thousands of patients and demonstrated there is a benefit of
OPCAB with respect to those end points.
Dr Bonchek, you also commented that the creatine kinase MB
release is understandable and therefore unimportant. I am not sure
that I would agree with that logical step. I do think that it is
understandable. I do think that applying a crossclamp to the aorta
and inducing global myocardial ischemia is responsible for the
creatine kinase MB release. I am not sure that the application of a
clamp and global ischemia is therefore unimportant. The clinical
significance of it may become more apparent as we more carefully
examine why length of stay is shorter for OPCAB and whether
longitudinal follow-up reveals these patients to have a different set
of cardiac outcomes.
Your final question related to the generalizability of these
results among other surgeons. It is true that OPCAB has a long
learning curve; it does require a certain devotion to the field and
a certain persistence in developing one’s own technique. I
personally enjoy the operation. I know that there are others who
do not. I do think that you will find that surgeons who choose
to take up this operation and perfect their own skills will be able
to achieve every bit as good results as I have demonstrated
today.
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